Related Experiment Video
Updated: Mar 2, 2026

Induction and Analysis of Epithelial to Mesenchymal Transition
Published on: August 27, 2013
Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c-Met-Mediated
Yei-San Hsieh1, Chiung-Ho Liao2, Wan-Shen Chen3
1Department of Chest Surgery, Tao-Yuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan.
Abstract:
Epithelial-to-mesenchymal transition (EMT) is a major process to regulate cell migration and invasion. Inhibition of epidermal growth factor receptor (EGFR)-mediated EMT by tyrosine kinase inhibitors (TKIs) is a strategy to prevent lung cancer invasion. However, drug resistance is emerged and accelerated invasion through other signaling bypassing EGFR after TKIs therapy. c-Met signaling pathway is highly activated in EGFR-mutated lung cancer cells. Targeting c-Met signaling pathway may be a strategy to suppress EGFR-independent migration and invasion for lung cancer therapy. Therefore, we examined the anti-migration and anti-invasion abilities of shikonin, an active compound from Lithospermum erythrorhizon, in highly and ligand-induced c-Met activation lung cancer cells. Our results revealed that cell viability and cell cycle progression did not change under 1 μM of shikoinin treatment in highly c-Met expressive HCC827 lung cancer cells. Endogenous c-Met activation was dose-dependently inhibited and the migration and invasion activity of HCC827 cells were suppressed by shikonin treatment. Induction of E-cadherin expression and inhibition of vimentin, slug, and snail expression by shikonin was through c-Met-mediated PI3K/Akt and ERK signaling suppression. Furthermore, hepatocyte growth factor (HGF)-induced migration, invasion and EMT marker change were reversed by shikonin in low c-Met expressive A549 lung cancer cells. Inhibition of HGF-induced c-Met, PI3K/Akt and MEK/ERK activation were observed in shikonin-treated cells. Co-treatment of PI3K/Akt inhibitor or ERK inhibitor with shikonin enhanced shikonin-reversed HGF-regulated EMT marker expression. Taken together, the results suggested that the anti-migration and anti-invasion activities of shikonin was through c-Met inhibition and following by EMT suppression in lung cancer. J. Cell. Biochem. 118: 4639-4651, 2017. © 2017 Wiley Periodicals, Inc.
Insights
Shikonin inhibits cancer cell migration and invasion by targeting the c-Met signaling pathway, suppressing epithelial-to-mesenchymal transition (EMT). This compound offers a potential therapeutic strategy for lung cancer, overcoming resistance to EGFR inhibitors.
Area of Science:
- Molecular Biology
- Cancer Research
- Pharmacology
Background:
- Epithelial-to-mesenchymal transition (EMT) drives cancer cell migration and invasion.
- Resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in lung cancer is linked to alternative signaling pathways.
- The c-Met signaling pathway is frequently activated in EGFR-mutated lung cancers and promotes invasion.
Purpose of the Study:
- To investigate the anti-migration and anti-invasion potential of shikonin, a Lithospermum erythrorhizon compound.
- To evaluate shikonin's effects on c-Met signaling and downstream pathways in lung cancer cells.
- To determine if shikonin can suppress EGFR-independent lung cancer cell invasion and EMT.
Main Methods:
- Assessed shikonin's effect on cell viability and cell cycle in HCC827 lung cancer cells.
- Examined shikonin's impact on endogenous and hepatocyte growth factor (HGF)-induced c-Met activation, migration, and invasion.
- Analyzed shikonin's modulation of EMT markers (E-cadherin, vimentin, slug, snail) and signaling pathways (PI3K/Akt, ERK).
Main Results:
- Shikonin (1 μM) did not affect cell viability or cycle progression in HCC827 cells.
- Shikonin dose-dependently inhibited c-Met activation, suppressing migration and invasion in HCC827 cells.
- Shikonin induced E-cadherin and inhibited vimentin, slug, and snail via suppression of c-Met-mediated PI3K/Akt and ERK signaling.
- Shikonin reversed HGF-induced migration, invasion, and EMT marker changes in A549 cells by inhibiting c-Met, PI3K/Akt, and MEK/ERK activation.
Conclusions:
- Shikonin exhibits anti-migration and anti-invasion activities in lung cancer cells.
- Shikonin functions by inhibiting the c-Met signaling pathway, leading to the suppression of EMT.
- Targeting c-Met with shikonin represents a potential therapeutic strategy for overcoming resistance in lung cancer therapy.
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Cell Migration through Invadopodia
Mitogens and the Cell Cycle

